Charles D. Blanke
Charles D. Blanke, MD, FASCO, FAWM

Chair, SWOG Cancer Research Network

Latest Stories

Guest Editorial
On behalf of the millions of Americans with cancer, whose very lives depend on our nation’s investment in oncology research, we ask that you join us now in urging congressional lawmakers to do the right thing: pass robust funding for the National Institutes of Health and the National Cancer Institute.
COVID-19 & CancerFreeGuest Editorial
While the National Clinical Trials Network (NCTN) groups remain open for business during the pandemic, it’s not business as usual. For good reason, clinical trials are taking a backseat to clinical care. Leadership and members themselves face significant challenges treating oncology patients, as attention and resources are diverted to minister to those with COVID-19.
FreeGuest Editorial
Oncologists must confront end-of-life issues on a nearly daily basis. Our approach to the potential death of a patient may change over time, however, depending on the patients' diagnosis and stage, where those patients are in their treatment plan, and, of course, what the patients' wishes are. When feasible, our primary goal is to prevent death from cancer, and when we cannot achieve that, we try to delay death as long as we can. When dying seems inevitable, we do our best to make it as comfortable as possible.